Abstract: Provided herein is a recombinant antibody or an epitope binding fragment thereof that specifically binds to a lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) epitope, as well as compositions and methods using these antibodies and fragments for therapeutic and diagnostic protocols.

Abstract: Provided herein are methods of inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof by administering an immunogenic composition to the subject, wherein the subject exhibits: an increase in antigen-specific cellular immune response as measured by Interferon-gamma (IFN-?) Enzyme-linked Immunospot (ELISpot) assay relative to baseline; and/or an increase in neutralizing antibody response as measured by a pseudovirus neutralizing assay relative to baseline.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.

Abstract: Disclosed herein are compositions comprising a recombinant nucleic acid sequence encoding a bispecific immune cell engaging antibody (DICE), a recombinant nucleic acid sequence encoding a bispecific T cell engaging (DBiTE) antibody, a fragment thereof, a variant thereof, or a combination thereof.

Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Powassan virus (POWV) antigen that elicits an immune response in a mammal against POWV virus, and methods of use thereof.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. Method of preventing infection by CCHFV and methods of treating individuals infected with CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.

Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.

Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Nipah virus (NiV) antigen that elicits an immune response in a mammal against NiV virus, and methods of use thereof.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acids are disclosed that comprise the sequences that encodes consensus RSV F protein or immuno-genic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Methods of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.

Abstract: The present invention relates to a humanized mouse, methods for generating a humanized mouse, and methods of using the humanized mouse for testing a vaccine, drug or treatment. Also provided are other uses for the humanized mouse.

Abstract: The present invention relates to recombinant optimized polynucleotide encoding a cytokine or cytokine receptor and to methods of making a recombinant optimized polynucleotide encoding a cytokine or cytokine receptor.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Respiratory Syncytial Virus antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Respiratory Syncytial virus infection in a subject using said composition and method of generation.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets PCSK9. The disclosure also provides a method of preventing and/or treating disease, such as cardiovascular disease or hypercholesterolemia, in a subject using the composition of the invention.

Abstract: Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.

Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in dogs, and in particular, vaccines that treat and provide protection against tumor growth.

Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus serotype O (FMDV-O) immunogenic proteins and nucleic acid molecule encoding such proteins and to methods for inducing immune responses against FMVD-O.

Abstract: Disclosed herein is a therapeutic comprising hypoxia inducible factor-1 alpha (HIF-1?). Also disclosed herein is a method for treating hypoxia or ischemia in a subject in need thereof. The method may comprise administering the vaccine to the subject in need thereof.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.